{"a":[{"_":"GSK axes key cough drug candidate after phase 3 data end blockbuster hopes","$":{"href":"/biotech/gsk-axes-key-cough-drug-candidate-after-phase-3-data-disappoint","hreflang":"en"}}]}
Phase 3negativecamlipixantNegative
AI Analysis
Summary
GSK terminated development of camlipixant for chronic cough following mixed Phase 3 data results. The decision eliminates a previously anticipated 2026 blockbuster catalyst for the pharmaceutical company.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
mixed phase 3 data led to development termination
Importance:8/10
Sentiment:
-0.85
drug discontinuationphase 3 failurechronic coughclinical trial
Related Companies
Read the original article
Published by FierceBiotech on July 17, 2026 5:47 AM